Skip to main content

Utility Menu

  • COVID-19
  • Meetings
  • News
  • Journal
  • Learning Center
  • Member Login
Home

Main navigation

  • About Us
    • Board of Directors
    • Committees
    • Diversity, Equity and Inclusion Policy
    • Event Endorsement Guidelines
    • Financials
    • HFSA Staff
    • Sponsorship
    • Strategic Plan
  • Membership
    • Join or Renew
    • Membership Benefits and Types
    • Membership Directory
    • Member Login
    • Corporate Membership
  • Professional Development
    • Awards
    • Continuing Education
      • HFSA Annual Scientific Meeting 2021
      • HFSA Virtual Board Certification Review 2021
    • HFSA Heart Failure Certification HF-Cert
    • Optimal Medical Therapy in HF Certificate Program
    • Fellowship Designation Program (FHFSA)
    • ERAS/NRMP Match for AHFTC Fellowship
    • HFSA Career Center
    • HFSA Learning Center
    • Heart Failure Beat Podcast
  • Research
    • Heart Failure Beat Podcast
    • Journal of Cardiac Failure
    • HFSA Clinical Documents
    • Surveys
    • HFSA Heart Failure Research Network
    • Industry News
    • Universal Definition and Classification of Heart Failure
  • Advocacy
  • Patient Hub
    • Learn About Heart Failure
    • Heart Failure Awareness 365
    • Heart Failure Beat Healthy Living Podcast
    • Additional Resources for Patients
    • Patient News
    • Patient Resources for Providers
    • Heart Failure Awareness Week 2021
  • Coronavirus (COVID-19) Resources
  • COVID-19
  • Meetings
  • News
  • Journal
  • Learning Center
  • Member Login
Facebook
Youtube
Twitter
Linkedin

Breadcrumb

  1. Home
  2. Industry News

Industry News

U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb’s Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

  • Read more about U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb’s Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Novartis Entresto® granted expanded indication in chronic heart failure by FDA

  • Read more about Novartis Entresto® granted expanded indication in chronic heart failure by FDA

Merck Announces U.S. FDA Approval of VERQUVO® (vericiguat)

  • Read more about Merck Announces U.S. FDA Approval of VERQUVO® (vericiguat)

US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction

  • Read more about US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction

New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status

  • Read more about New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status

Amgen, Cytokinetics And Servier Announce Topline Results From GALACTIC-HF, A Phase 3 Trial Of Omecamtiv Mecarbil In Patients With Heart Failure

  • Read more about Amgen, Cytokinetics And Servier Announce Topline Results From GALACTIC-HF, A Phase 3 Trial Of Omecamtiv Mecarbil In Patients With Heart Failure

Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash

  • Read more about Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash

Jardiance® reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25% in adults with and without diabetes who had heart failure with reduced ejection fraction

  • Read more about Jardiance® reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25% in adults with and without diabetes who had heart failure with reduced ejection fraction

Farxiga demonstrated unprecedented reduction in the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease in the Phase III DAPA-CKD trial

  • Read more about Farxiga demonstrated unprecedented reduction in the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease in the Phase III DAPA-CKD trial

Jardiance® meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes

  • Read more about Jardiance® meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes

Pagination

  • Page 1
  • Next page ››
Subscribe to Industry News

Leading experts on heart failure care

Our vision is to significantly reduce the burden of heart failure and provide a platform for collaboration, education, innovation, research, and advocacy to improve and expand care.

Learn more About HFSA

Get in touch

9211 Corporate Blvd., Suite 270 Rockville, MD 20850
(301) 312-8635
info@hfsa.org
Facebook
Youtube
Twitter
Linkedin

Footer menu

  • Contact
  • Media Center
  • Privacy Policy & Terms of Use